Health Catalyst, Inc. (NASDAQ:HCAT) Receives Consensus Rating of “Moderate Buy” from Brokerages

Health Catalyst, Inc. (NASDAQ:HCAT) has been assigned a consensus rating of “Moderate Buy” from the eleven brokerages that are currently covering the stock, Marketbeat reports. Four analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $12.10.

A number of research analysts have recently issued reports on HCAT shares. Piper Sandler reiterated an “overweight” rating and set a $15.00 price target (down from $17.00) on shares of Health Catalyst in a research note on Friday, February 23rd. Guggenheim raised shares of Health Catalyst from a “neutral” rating to a “buy” rating and set a $14.00 price target on the stock in a research note on Friday, January 26th. Evercore ISI decreased their target price on shares of Health Catalyst from $11.00 to $10.00 and set an “outperform” rating on the stock in a research report on Friday, February 23rd. Canaccord Genuity Group dropped their price objective on shares of Health Catalyst from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Friday, February 23rd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $16.00 price target on shares of Health Catalyst in a research report on Wednesday, April 10th.

Health Catalyst Price Performance

HCAT stock opened at $6.65 on Thursday. The business’s 50-day moving average is $7.08 and its two-hundred day moving average is $8.16. The company has a debt-to-equity ratio of 0.62, a current ratio of 4.42 and a quick ratio of 4.42. The firm has a market capitalization of $392.55 million, a P/E ratio of -3.17 and a beta of 1.32. Health Catalyst has a 1 year low of $5.45 and a 1 year high of $14.37.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings results on Thursday, February 22nd. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.06. The firm had revenue of $75.08 million during the quarter, compared to the consensus estimate of $73.67 million. Health Catalyst had a negative return on equity of 12.19% and a negative net margin of 39.92%. Analysts anticipate that Health Catalyst will post -0.47 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Health Catalyst

A number of institutional investors and hedge funds have recently bought and sold shares of HCAT. Impax Asset Management Group plc grew its stake in Health Catalyst by 52.0% during the 4th quarter. Impax Asset Management Group plc now owns 1,754,475 shares of the company’s stock valued at $16,246,000 after acquiring an additional 600,000 shares in the last quarter. Primecap Management Co. CA boosted its stake in shares of Health Catalyst by 86.3% during the 3rd quarter. Primecap Management Co. CA now owns 1,120,438 shares of the company’s stock worth $11,339,000 after acquiring an additional 519,004 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Health Catalyst by 124.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 854,896 shares of the company’s stock valued at $8,652,000 after acquiring an additional 473,323 shares in the last quarter. Essex Investment Management Co. LLC bought a new position in shares of Health Catalyst in the 1st quarter valued at approximately $1,848,000. Finally, ClariVest Asset Management LLC lifted its holdings in Health Catalyst by 303.9% in the 1st quarter. ClariVest Asset Management LLC now owns 282,325 shares of the company’s stock worth $2,126,000 after purchasing an additional 212,425 shares during the last quarter. 85.00% of the stock is owned by institutional investors and hedge funds.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.